 Cookies help identify the right message.

We would like to use anonymous analytics cookies to help improve our website experience. View our cookie policy.

Skip to content
Pipeline Investors News Join us Contact

Contact Us

  • +44 [0] 20 4551 8888
  • contact@tangramtx.com
  • Tangram Therapeutics on LinkedIn
  • Tangram Therapeutics on X
Tangram Therapeutics | Committed to uniting computation, RNAi, and unconventional thinking to make better medicines faster.
  • About[+]
    • About[+]
      • Why Tangram?Explore more about how and why Tangram Therapeutics exists.
      • LeadershipDiscover the people leading the way in relentless medicine discovery.
  • Pipeline
  • Our science[+]
    • Our Science[+]
      • Our ApproachWe reduce the risks of making impactful medicine a reality.
      • LLibraConnecting extensive data and information with AI, powering GalOmic drug discovery.
      • GalOmicEnabling the generation of Tangram Therapeutics' potent and long-acting RNAi medicines.
  • Investors
  • News
  • Join us
  • Contact
Menu
Press release

Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate

26 November 2025

  • Press release

Tangram Therapeutics to Participate in Upcoming Investor and Scientific Conferences

Oct 3, 2025

  • Press release

e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS

Oct 1, 2025

  • Press release

e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical Data

Jul 10, 2025

  • Press release

e-therapeutics presents new data supporting ETX‑312 as a differentiated, disease-modifying near-clinic GalOmic Treatment for MASH

May 7, 2025

  • Press release

e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025

Feb 5, 2025

  • Press release

e-therapeutics Announces Business Updates and Interim Results

Oct 31, 2024

  • Press release

e-therapeutics to Present at Upcoming Scientific Meetings

Oct 3, 2024

  • Press release

Results of Annual General Meeting and Appointment of Jeremy Punnett to the Board of Directors

Jul 16, 2024

  • Press release

e-therapeutics announces completion of £28.90 million fundraise

Jul 3, 2024

  • Press release

Pipeline update and final results for the year ended 31 January 2024

Jun 6, 2024

  • Press release

Lord David Prior Appointed as Chair of e‑therapeutics’ Board of Directors

May 23, 2024

  • Press release

Last Day of Dealings on AIM

May 8, 2024

  • Press release

Result of General Meeting

Apr 29, 2024

  • Press release

Proposed Fundraise of £28.9m and Cancellation

Apr 10, 2024

  • Press release

Business Update

Jan 16, 2024

  • Press release

Interim Results for the financial year 2023/2024

Oct 26, 2023

  • Press release

Final results for the year ended 31 January 2023

May 4, 2023

  • Press release

Filing of four new patent applications

Feb 7, 2023

  • Press release

Successful completion of £13.5 million fundraise

Sep 30, 2022

  • Press release

Interim Results for the financial year 2022/2023

Sep 30, 2022

  • Press release

Filing of eight patent applications on proprietary GalNAc-siRNA technology and target related innovation

Aug 1, 2022

  • Press release

Result of Annual General Meeting

Jul 20, 2022

  • Press release

Director Dealing and Issue of Equity

Jul 5, 2022

  • Press release

Notice of Annual General Meeting and Posting of Annual Report and Accounts

May 17, 2022

RELENTLESS
CREATIVITY

London HQ

  • Floor 4, 4 Kingdom Street
    Paddington Central London W2 6BD

[LOCAL TIME]

Company

  • About
  • Our Approach
  • Pipeline
  • Investors
  • News
  • Careers
  • Leadership
  • Contact

© 2026 Tangram Therapeutics. Brand and website by UnitedUs. V3.3

  • Press Release Sign Up
  • Sitemap
  • Accessibility
  • Privacy
  • Tangram Therapeutics on LinkedIn
  • Tangram Therapeutics on X

OUR TRANSFORMATION INTO TANGRAM

Pioneering advancements in drug development takes steadfast persistence. A ceaseless evolution of understanding and innovation. That’s why E-Therapeutics has transformed into Tangram Therapeutics. The new brand embodies the expedited exploration needed to unlock life-transforming RNAi medicines faster. Breaking conventions of slow science, Tangram makes sense of patterns to find new answers. Our transformation into Tangram reveals the robust focus necessary for relentless medicine discovery.

Discover our new identity